In a meta-analysis comparing the efficacy of GLP-1 receptor agonists versus metformin in PCOS patients, GLP-1 receptor agonists were superior to metformin at improving HOMA-IR-based insulin sensitivity and lowering body mass index (Han et al. 2019). Here, GLP1R is linked to polycystic ovary syndrome.